Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenströms macroglobulinemia (WM) from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Dr Garcia-Sanz comments on the current limitations of treatments available for WM, including toxicities and the need for multiple agents. Novel BTK inhibitors hold promise for these patients, with ibrutinib in combination with rituximab showing positive results when compared to rituximab alone.
Novel BTK inhibitors for Waldenström’s macroglobulinemia
